atai Life Sciences (ATAI) announced that it has been awarded a multi-year, milestone-driven grant worth up to $11.4 million by the National Institute on Drug Abuse, NIDA, part of the National Institutes of Health, NIH. The UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder, OUD. “The commitment of Federal support to advance innovative and differentiated research in OUD highlights the devastating toll this crisis continues to take on individuals, families, and communities,” said Srinivas Rao, M.D., Ph.D., Chief Executive Officer and Co-founder of atai. “This investment demonstrates the urgent need for evidence-based prevention, treatment, and long-term recovery solutions that can truly make a difference.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Cathie Wood Invests $37M into Biotech Stocks, Trims Stake in KTOS, TEM, and ROKU Stocks
- ATAI Life Sciences: Advancements in Psychedelic Therapies Justify Buy Rating
- Psychedelic: Exclusive talk with biopharma company Reunion Neuroscience
- ATAI Life Sciences: Promising Outlook with Strategic Moves and Strong Financial Position
- ATAI Life Sciences: Positioned for Growth in Psychedelic Medicine with Promising Developments and Strategic Partnerships